A biosimilar is a biological medication that is highly similar to an already approved biologic drug, with no clinically meaningful differences in safety or effectiveness. Think of it as the biologic equivalent of a generic drug, though the comparison isn’t quite that simple. Since the FDA began approving them in 2015, 63 biosimilars have been approved for 17 different reference products, and their sales prices average 50% less than the original biologic at the time of launch.
Why Biosimilars Aren’t Exactly Like Generics
Generic drugs are chemically identical copies of small-molecule medications, things like ibuprofen or metformin. These are relatively simple chemicals that can be reproduced atom for atom. Biologics are fundamentally different. They’re large, complex proteins made inside living cells, typically mammalian cell lines grown under tightly controlled conditions. Slight deviations in pH, temperature, or nutrient levels during manufacturing can alter the final product. Because of this complexity, no two batches of any biologic, even from the same manufacturer, are perfectly identical.
This natural batch-to-batch variation is why the term “biosimilar” exists instead of “biocopy” or “biogeneric.” A biosimilar manufacturer can’t simply replicate a chemical formula. They must develop their own living cell lines and manufacturing processes, then prove the resulting product is highly similar to the original. Minor differences in clinically inactive components are expected and acceptable. What matters is that these differences don’t change how the drug works in your body.
How Biosimilars Get Approved
The approval process for a biosimilar is rigorous but distinct from what the original biologic went through. The original drug had to prove it was safe and effective from scratch. A biosimilar doesn’t need to re-prove that the drug concept works. Instead, the manufacturer must demonstrate through extensive head-to-head comparisons that their version performs the same way as the original.
This starts with detailed structural and functional analysis, comparing the biosimilar’s molecular makeup to the reference product. If questions remain after that stage, manufacturers move to animal studies, then human studies measuring how the drug behaves in the body. Clinical trials for biosimilars use an equivalence design: the goal is to show the biosimilar is neither worse nor better than the original, confirming it behaves the same way. These trials also evaluate safety and whether the drug triggers unwanted immune responses.
One notable feature of the approval process is extrapolation. If a biosimilar proves equivalent to its reference product in one condition, regulators can approve it for other conditions the original treats without requiring separate clinical trials for each one. This must be scientifically justified, but it helps keep development costs lower, which ultimately contributes to lower prices for patients.
What Makes Biologics So Hard to Copy
The manufacturing challenge behind biosimilars explains a lot about why they cost what they do and why they can’t simply be stamped out like a generic pill. Biologics are produced using mammalian cells because those cells can fold proteins correctly and add the chemical modifications the proteins need to function. But mammalian cells are fragile. They lack cell walls, making them vulnerable to physical stress during production. The growth media they require is far more complex than what simpler organisms like bacteria need.
Every step of the process, from maintaining the cell culture to purifying the final protein, must be precisely controlled. This is why even the original manufacturer can’t guarantee identical batches. For a biosimilar maker starting from scratch with different cell lines and equipment, the challenge is even greater. The investment required to develop a biosimilar typically runs into the hundreds of millions of dollars, which is far less than developing an original biologic but far more than producing a generic pill.
Interchangeability and Pharmacy Substitution
Not all biosimilars carry the same designation. Some are approved as “interchangeable,” which is a higher standard. An interchangeable biosimilar can be substituted by a pharmacist at the pharmacy counter without the prescribing doctor needing to write a new prescription, much like how a pharmacist can swap a brand-name pill for its generic.
In practice, the rules around substitution vary by state. Some states require the pharmacist to get the prescriber’s express authorization before making the switch. Others require notification within five days after the substitution. Most states also require that you, the patient, be told at the point of dispensing that a substitution has occurred. Pharmacists must keep records of any substitution, and many states require labeling that explicitly states a swap was made. If your doctor prescribes a biologic and you receive a biosimilar at the pharmacy, these rules are why you’ll typically be informed about it.
How Biosimilars Are Named
To help distinguish between products, the FDA requires all biologics (including biosimilars) to carry a unique nonproprietary name. This name combines the core drug name with a four-letter suffix that has no specific meaning. For example, you might see a product called “adalimumab-xxxx,” where “xxxx” is a random string of lowercase letters. This system exists so that doctors, pharmacists, and safety monitoring systems can track exactly which product a patient received, which becomes important if a side effect is reported.
Safety Monitoring After Approval
Because biologics are made from living systems, their safety monitoring extends well beyond the initial approval. Manufacturers must submit periodic safety reports and maintain risk management plans throughout a product’s life on the market. These plans outline how a company will identify, track, and minimize any important risks over time.
Immunogenicity, meaning the chance that your immune system reacts against the drug itself, is a particular focus. All biologic proteins can potentially trigger immune responses, and this risk is evaluated before approval and monitored continuously afterward. In Europe, newly approved biosimilars are flagged with a black triangle symbol on their packaging, signaling that the product is under intensified monitoring during its first years on the market. Manufacturers are also expected to conduct post-approval studies, often involving more than 200 patients, typically completed within two years of launch.
When side effects are reported, including the brand name and batch number helps manufacturers trace whether a problem is linked to a specific production run. This level of traceability is one reason the naming and record-keeping requirements exist.
Cost Savings for Patients
The primary promise of biosimilars is affordability. Biologic drugs treat some of the most common and expensive chronic conditions, including rheumatoid arthritis, cancer, diabetes, and inflammatory bowel disease. Many of these treatments cost tens of thousands of dollars per year. When biosimilar competition enters the market, the sales price drops by roughly 50% compared to what the original biologic cost at the time of the biosimilar’s launch.
With 63 biosimilars now approved in the U.S. across 17 different reference products, the options available to patients continue to grow. The practical impact depends on your insurance coverage and which biosimilars your plan covers, but the overall trend is toward more treatment choices at lower cost. For conditions requiring long-term biologic therapy, even a partial reduction in price can translate to thousands of dollars saved annually.